维A酸（CAS 302-79-4）：分子式 C20H28O2、分子量 300.4。
| CAS号 | 302-79-4 |
|---|---|
| 分子式 | C20H28O2 |
| 分子量 | 300.4 |
| 熔点 | 354 to 360 °F (NTP, 1992) |
| LogP | 6.3 |
| 应用领域 | Uses: Antineoplastic Agents Keratolytic Agents、MEDICATION、Synthetic Polymer MALDI Matrix Compounds、Use (kg、approx.) in Germany (2009): >10、Use (kg) in USA (2002): 364、Consumption (g per capita、approx.) in Germany (2009): 0.000122、Consumption (g per capita) in the USA (2002): 0.00129、Calculated removal (%): 98.9、For the the induction of remission in patients with acute promyelocytic leukemia (APL)、French-American-British (FAB) classification M3 (including the M3 variant)、For the topical treatment of acne vulgaris、flat warts and other skin conditions (psoriasis、ichthyosis congenita、icthyosis vulgaris、lamellar icthyosis、keratosis palmaris et plantaris、epidermolytic hyperkeratosis、senile comedones、senile keratosis、keratosis follicularis (Darier's disease)、and basal cell carcinomas.)、For palliative therapy to improve fine wrinkling、mottled hyperpigmentation、roughness associated with photodamage.、Methods of Manufacturing: By oxidation of vitamin A aldehyde which may be obtained by oxidation of vitamin A.、R. Marbet、German patent 2061507、United States of America patent 3746730 (1971、1973 both to Hoffmann-La Roche).、Formulations、Preparations: Oral: Capsules 10 mg、Vesanold (Roche)、Table: Tretinoin (Topical) Preparations [Table#3901]、General Manufacturing Information: Retinoic acid: ACTIVE |
登记用途：Uses: Antineoplastic Agents Keratolytic Agents、MEDICATION、Synthetic Polymer MALDI Matrix Compounds、Use (kg、approx.) in Germany (2009): >10、Use (kg) in USA (2002): 364、Consumption (g per capita、approx.) in Germany (2009): 0.000122、Consumption (g per capita) in the USA (2002): 0.00129、Calculated removal (%): 98.9、For the the induction of remission in patients with acute promyelocytic leukemia (APL)、French-American-British (FAB) classification M3 (including the M3 variant)、For the topical treatment of acne vulgaris、flat warts and other skin conditions (psoriasis、ichthyosis congenita、icthyosis vulgaris、lamellar icthyosis、keratosis palmaris et plantaris、epidermolytic hyperkeratosis、senile comedones、senile keratosis、keratosis follicularis (Darier's disease)、and basal cell carcinomas.)、For palliative therapy to improve fine wrinkling、mottled hyperpigmentation、roughness associated with photodamage.、Methods of Manufacturing: By oxidation of vitamin A aldehyde which may be obtained by oxidation of vitamin A.、R. Marbet、German patent 2061507、United States of America patent 3746730 (1971、1973 both to Hoffmann-La Roche).、Formulations、Preparations: Oral: Capsules 10 mg、Vesanold (Roche)、Table: Tretinoin (Topical) Preparations [Table#3901]、General Manufacturing Information: Retinoic acid: ACTIVE。
维A酸 是一种化工化合物，登记 CAS 号为 302-79-4，分子式 C20H28O2（分子量 300.4）。
登记 CAS 号：302-79-4
其分子式 C20H28O2 由 20 个碳、28 个氢、2 个氧 组成。
别名/同义词：维A酸 · Tretinoin
维A酸 的 CAS 登记号为 302-79-4。
分子式 C20H28O2，分子量 300.4。
别名/同义词：维A酸、Tretinoin。
登记用途：Uses: Antineoplastic Agents Keratolytic Agents、MEDICATION、Synthetic Polymer MALDI Matrix Compounds、Use (kg、approx.) in Germany (2009): >10、Use (kg) in USA (2002): 364、Consumption (g per capita、approx.) in Germany (2009): 0.000122、Consumption (g per capita) in the USA (2002): 0.00129、Calculated removal (%): 98.9、For the the induction of remission in patients with acute promyelocytic leukemia (APL)、French-American-British (FAB) classification M3 (including the M3 variant)、For the topical treatment of acne vulgaris、flat warts and other skin conditions (psoriasis、ichthyosis congenita、icthyosis vulgaris、lamellar icthyosis、keratosis palmaris et plantaris、epidermolytic hyperkeratosis、senile comedones、senile keratosis、keratosis follicularis (Darier's disease)、and basal cell carcinomas.)、For palliative therapy to improve fine wrinkling、mottled hyperpigmentation、roughness associated with photodamage.、Methods of Manufacturing: By oxidation of vitamin A aldehyde which may be obtained by oxidation of vitamin A.、R. Marbet、German patent 2061507、United States of America patent 3746730 (1971、1973 both to Hoffmann-La Roche).、Formulations、Preparations: Oral: Capsules 10 mg、Vesanold (Roche)、Table: Tretinoin (Topical) Preparations [Table#3901]、General Manufacturing Information: Retinoic acid: ACTIVE。
维A酸（CAS 302-79-4）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 302-79-4 |
|---|---|
| PubChem CID | 444795 |
| Molecular formula | C20H28O2 |
| IUPAC name | (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid |
| UNII (FDA) | 5688UTC01R |
| Molecular Weight | 300.4 |
|---|---|
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 300.208930132 |
| Monoisotopic Mass | 300.208930132 |
| Topological Polar Surface Area | 37.3 |
| Heavy Atom Count | 22 |
| Melting Point | 354 to 360 °F (NTP, 1992) |
|---|---|
| Melting Point | 178-184 |
| Melting Point | 180-182 °C |
| Melting Point | 181 °C |
| LogP | 6.3 |
| LogP | log Kow = 6.30 |
| LogP | 6.30 |
| Collision Cross Section | 182.1 Ų [M+Na]+ |
Retinoic acid; tretinoin; 302-79-4; all-trans-Retinoic acid; Vitamin A acid; trans-Retinoic acid; ATRA; Aberel; Eudyna; Dermairol; Renova; all-trans-Vitamin A acid; Cordes vas; Retin A; Tretin M; all-trans-Tretinoin
| Reported hazard statements | H302 (29.8%), H315 (73.4%), H319 (16.5%), H335 (14.9%), H360 (72.9%), H400 (59%), H410 (58%), H411 (16%) |
|---|
H302 (29.8%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (73.4%): Causes skin irritation [Warning Skin corrosion/irritation]
Tretinoin · CAS 302-79-4 · C20H28O2. UNII 5688UTC01R. Melting Point: 354 to 360 °F (NTP, 1992); Melting Point: 178-184; Melting Point: 180-182 °C.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Tretinoin